P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (20th June 2018) - Domenyuk, V; Liu, X; Magee, D; Gatalica, Z; Stark, A; Kennedy, P; Rosenow, M; Barker, A; Berry, D; Poste, G; Halbert, D; Hart, C; et al.